Skip to content

Main Navigation

Clinical Study

COVID-19 Plasma study to limit complications from coronavirus

This research is being done to develop a possible new therapy for prevention and treatment of coronavirus disease (COVID-19).We would like to study whether human plasma containing antibodies to the SARS- CoV-2 virus could be an option for prevention and treatment of COVID-19. This type of treatment, known as passive antibody therapy, could be a way of rapidly treating patients when there are sufficient numbers of people who have recovered from infection and can donate antibody-containing plasma. We hope that it will either prevent illness caused by coronavirus or lessen the severity of symptoms.


For more information contact:

Evan Heller

IRB#: IRB_00136298 | PI: J. Robinson Singleton | Department: NEUROLOGY | Approval Date: 2020-10-09 17:53:00
Study Categories: COVID-19 Studies | Specialties: Infectious Diseases

Who can participate?

 Gender: All

 Age: Over 18 years old

 Volunteers: Healthy Volunteers

 Location: In Person

 COVID-19 Study

Inclusion Criteria:

  • Must be 18 years old or older
  • If you wish to participate, you will need to enroll within 96 hours of a high-risk exposure, as defined by the CDC

Exclusion Criteria:

  • You cannot participate if you have received blood products, such as a transfusion, etc., in the past 120 days
  • You cannot participate if you have a medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that the study doctor feels could affect your safety or ability to participate
  • You cannot participate if you have active symptoms of COVID-19 when you are screened for this study. Symptoms include respiratory infection involving cough, fever, shortness of breath.
  • You cannot participate if you have laboratory evidence of COVID-19 infection at time of screening
  • You cannot participate if you have had certain allergic reactions to blood products

Will I be paid for my time?


Last Updated: 4/5/21